Skip to main content
. 2023 Jan 28;38(5):485–499. doi: 10.1007/s10654-022-00956-4

Fig. 2.

Fig. 2

Linear dose-response analysis of Lp(a) per 50 mg/dL and A) All-cause mortality in general population, B) All-cause mortality in patients with CVD, C) CVD- death in general population, D) CVD-death in patients with CVD, E) Non-CVD-death in general population. *ERFC: The emerging risk factor collaboration. Zwinger*: Validation study 1; Zwinger**: Validation study 2; Zwinger***: Validation study 3; Welsh^: High risk cohort